^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IO120

    i
    Other names: IO120, PD-L2 peptide vaccine, IO 120
    Associations

    News

    Trials
    Company:
    IO Biotech
    Drug class:
    PD-L2 inhibitor
    Associations

    News

    Trials
    over2years
    Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia. (clinicaltrials.gov)
    P2, N=19, Completed, Lars Møller Pedersen | Active, not recruiting --> Completed
    Trial completion • IO biomarker
    |
    IGH (Immunoglobulin Heavy Locus)
    |
    IO103 • IO120
    over3years
    Peptide Vaccination With IO103 and IO120 in Patients With Chronic Lymphocytic Leukemia. (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, Lars Møller Pedersen | Trial completion date: Oct 2020 --> Mar 2021 | Trial primary completion date: Oct 2020 --> Mar 2021
    Clinical • Trial completion date • Trial primary completion date • IO biomarker
    |
    IGH (Immunoglobulin Heavy Locus)
    |
    IO103 • IO120
    over4years
    Peptide Vaccination With IO103 and IO120 in Patients With Chronic Lymphocytic Leukemia. (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, Lars Møller Pedersen | Recruiting --> Active, not recruiting
    Clinical • Enrollment closed • PD(L)-1 Biomarker • IO biomarker
    |
    IGH (Immunoglobulin Heavy Locus)
    |
    IO103 • IO120